All treatments
Treatment
Javlor 25 mg/mL concentrate for solution for infusion clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer
This study compares a new medicine called Sacituzumab Govitecan with standard treatments for advanced bladder cancer that has spread or can't be removed. Researchers want to see if the new medicine helps people live longer and feel better.
For: Locally Advanced or Metastatic Unresectable Urothelial CancerItaly · France · Sweden - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations
This study looks at a new drug, erdafitinib, for people with advanced bladder cancer that has a specific gene change. It compares erdafitinib to standard treatments like pembrolizumab, docetaxel, or vinflunine to see if it helps people live longer.
For: Advanced Urothelial CancerFrance · Spain · Belgium